CCS
UPI

Crosspoint Capital Strategies’s UROPLASTY INC-NEW UPI Stock Holding History

Crosspoint Capital Strategies’s Portfolio UPI Stock Details UPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,900
Closed -$11K – 706
2014
Q1 		$11K Buy
+2,900
New +$11.3K ﹤0.01% 466

Other funds holding UPI

Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCP
Rothschild Capital Partners New York $408M AUM 25.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Crosspoint Capital Strategies's UPI Position: Q2 2014 in Review

Crosspoint Capital Strategies sold out of UROPLASTY INC-NEW (UPI) in Q2 2014, closing a stake of 2,900 shares — an estimated $11K sold.

Crosspoint Capital Strategies first reported a position in UPI in Q1 2014 and held it in 1 quarter. The position peaked at $11K in Q1 2014. 37 funds tracked by Wall St. Rank hold UPI as of Q2 2014.

  • Crosspoint Capital Strategies reported no remaining UROPLASTY INC-NEW position as of Q2 2014 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 2,900 UROPLASTY INC-NEW shares in Q2 2014, an estimated $11K.
  • Crosspoint Capital Strategies first reported a position in UROPLASTY INC-NEW in Q1 2014 and held it in 1 quarter.
  • Crosspoint Capital Strategies's UROPLASTY INC-NEW position peaked at $11K in Q1 2014.
  • 37 funds tracked by Wall St. Rank held UROPLASTY INC-NEW as of Q2 2014.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2014, filed 29 Jul 2014.